VM:CC - Voyageur Pharmaceuticals Publishes White Paper SmoothX: A Promising New Positive Oral Contrast Agent That Enhances Patient Satisfaction and Diagnostic Excellence in CT Imaging

(TheNewswire)

Calgary, Canada – TheNewswire- June 12, 2023 - Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( USA : VYYRF) ("Voyageur" orthe "Corporation"), a provider of innovative medical imagingsolutions, is pleased to announce the release of the white papertitled "SmoothX: A Promising New Positive Oral Contrast Agent forCT." Authored by Alec J. Megibow, MD, MPH, FACR, the white paperhighlights the remarkable imaging properties of Voyageur's product,SmoothX™, emphasising its potential to optimize abdominal CTexaminations and maximize patient satisfaction.

Oral contrast agents have long been vital in elevatingdiagnostic accuracy and effectiveness in medical imaging procedures.With the introduction of SmoothX, Voyageur is offering a positive oralcontrast agent that not only enhances diagnostic outcomes but alsoprovides a pleasant taste, enhancing patient satisfaction.

In a recent blinded study comparing SmoothX with theestablished oral contrast agent Readi-CAT2, Voyageur conducted adetailed evaluation, demonstrating that SmoothX exhibited nearlyidentical diagnostic imaging properties. This finding establishesSmoothX as a reliable alternative that maintains the uncompromisingstandards of image quality required for precise diagnosis.

Of notable importance is the taste test study conductedalongside the clinical evaluation. The results revealed a remarkablepreference for the palatable flavor of SmoothX among the majority ofthe participants compared to Readi-CAT2. This preference for SmoothX'staste has the potential to translate into heightened patientsatisfaction and increased compliance during abdominal CTexaminations.

Voyageur extends heartfelt appreciation to thededicated team at Canada Diagnostic Centre in Calgary for theirinvaluable participation in this study. Under the exceptionalleadership of Jay Zelazo, MD, FRCPC, Director of CT, along with JordanMuth, MRT (MR) , MRI &CT Manager, and Michelle Holstein, Radiological Technologist, MRT (R)(MR), the study was meticulously executed, contributing significantlyto the credibility and reliability of the findings.

SmoothX represents a leap forward in oral contrastagents for CT imaging, aiming to provide a superior patient experiencewhile ensuring optimal diagnostic outcomes. Voyageur remains steadfastin its commitment to continuous innovation, dedicated to improving thequality of care for patients worldwide.

For more information about SmoothX and other imagingsolutions offered by Voyageur, please visit https://voyageurpharmaceuticals.ca/ and contact Ethan Mohan, Voyageur Sales Manager at +1-403-803-0427 or ethan@vpharma.ca .

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadia n publiccompany trading under the symbol VM on the TSXV, is in development ofbarium, iodine and carbon Active Pharmaceutical Ingredients (API) andhigh-performance, cost-effective imaging contrast agents. With astrategic focus on vertically integrating thebarium, iodine and carbon contrast imaging market, Voyageur aims tobecome a key player by producing its own barium, iodine, and fullereneminerals.

Our business plan is set to generate cash flow bypartnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of our products byregulatory agencies worldwide. As we solidify our presence in themarket, we will transition into a high-margin domestic manufacturer ofradiology drugs, further expanding our revenue streams.

Voyageur is committed to sustainability andenvironmental stewardship. We envision a future where carbonneutrality is the norm, and to achieve this, we are buildingstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, we aimto become 100% self-sufficient across all our manufacturingactivities. Our commitment to the environment sets us apart as apioneer in the industry.

At the core of our operations, Voyageur owns a 100%interest in two barium sulphate (barite) projects, including theFrances Creek and Pedley Mountain property. Additionally, Voyageurholds interests in a high-grade iodine, lithium, and bromine brineproject situated in Utah, USA, further bolstering our position in theindustry. Voyageur owns a 100% interest in two battery mineralprojects which focus on copper/zinc development.

Our ambitious vision is to become the first verticallyintegrated, carbon-neutral company in the imaging contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to the final production, we plan to ensure unmatchedquality and cost efficiency. We embody the motto of " From the Earth to the Bottle ," highlighting our commitment to responsible sourcingand manufacturing practices.

For Further Information:

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Cautionary Statement Regarding “Forward-Looking”Information

This news releasemay contain certain forward-looking information and statements,including without limitation, statements pertaining to theeffectiveness of SmoothX as an oral contrast agent, the preference ofpatients for the taste of SmoothX, Voyageur's plans to become carbonneutral and Voyageur's ability to continuously innovate and improvethe quality of care for patients worldwide. All statements includedherein, other than statements of historical fact, are forward-lookinginformation and such information involves various risks anduncertainties. There can be no assurance that such information willprove to be accurate, and actual results and future events coulddiffer materially from those anticipated in such information. Adescription of assumptions used to develop such forward-lookinginformation and a description of risk factors that may cause actualresults to differ materially from forward-looking information can befound in the Company's disclosure documents on the SEDAR website atwww.sedar.com. Voyageur does not undertake to update anyforward-looking information except in accordance with applicablesecurities laws.

Copyright (c) 2023 TheNewswire - All rights reserved.